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Few areas in translational medicine have developed as
dynamically as research into the biology and treatment of
tumours of the nervous system. However, the outcome of
these efforts in terms of increased survival rates and
reduced mortality is still very moderate. Chemotherapy
with the simple alkylating agent, temozolomide, combined
with concurrent radiotherapy is still the most promising
approach in the treatment of glioblastomas while the
introduction of targeted therapy has had very limited suc-
cess. This is no reason to resign. In contrast, our efforts
should be increased, and for anybody working in this field
or planning to enter this research area, CNS Cancer is a
very good choice.
When reviewing a book, I usually ask three questions: Is
it comprehensive, timely and useful? CNS Cancer is not
comprehensive insofar as it basically deals with malignant
gliomas. Other CNS neoplasms, in particular those mani-
festing in children, are either not (ependymomas) or
insufficiently (medulloblastoma) dealt with.
The book starts with a section on animal models of
central nervous system tumours. There is detailed infor-
mation on the generation of brain tumours in genetically
modified mice, but also on animal models suitable for
preclinical therapeutic studies. While there are several
excellent mouse models of medulloblastoma, unfortunately
none is presented in detail. There is an informative article
on the genetic basis of brain tumour induction by N-nitroso
compounds in rodents, but a contribution specifically
dealing with neural progenitor cells would have been
welcome. Altogether, this section of the book contains very
useful information on a variety of models, but each of them
deals with a specific system, and an overview that would
assist the non-initiated reader would have been quite
useful.
The second part of the book deals with prognostic fac-
tors and biomarkers, sub-divided in 15 contributions that
cover all important aspects, with an emphasis on those with
a significant clinical impact. Most contributions focus on
imbalances in signalling pathways caused by genetic and
epigenetic alterations. However, there are also contribu-
tions on proteomics, the role of hypoxia and necrosis,
microRNAs and brain tumour stem cell markers. Erwin. G.
Van Meir, editor of the book, contributes a very informa-
tive review of the role of TP53 alterations in gliomas,
including recent efforts to re-establish the transcriptional
activity of mutated TP53 by small molecules. Altogether,
this is an excellent section. It should also be mentioned that
despite the time required for editing and publication, most
of the contributions are very timely, with references
reaching into 2008.
The last part of the book concentrates on therapeutic
targets, including angiogenesis and apoptosis, RAS and
STAT3 signalling, as well as antibody-mediated immuno-
therapy. Particularly interesting are the contributions on
brain cancer stem cells as therapeutic targets and the
approach of driving tumour stem cells into differentiation.
Gene therapy using herpes simplex virus 1 and adenovi-
ruses is described in sufficient detail, which is commend-
able, since this line of research is no longer funded as much
as it deserves. Conspicuously absent are contributions on
novel imaging techniques that may predict response to
therapy.
Altogether, this book is an excellent source for those
engaged in translational brain tumour research. I am not
aware of any other publication that could match CNS
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Cancer for this specific purpose. The editor has been able
to assemble a group of excellent authors with international
standing, and this is reflected by the quality of work
throughout the book. Brain Cancer contains a wealth of
information, is timely and very useful.
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